What is NeoGenomics's acquisitions?

NeoGenomics (NEO) reported acquisitions of $463K in Q3 2025.

What does acquisitions mean?

Cash paid for business acquisitions net of cash acquired in the target company — the primary M&A cash flow line.

NeoGenomics NEO Acquisitions

Acquisitions at other companies

Labcorp HoldingsLH

-$225.7M-2,357%

Quest DiagnosticsDGX

$38M—

Fulgent Genetics, Inc.FLGT

$55.57M—

Tempus AI, Inc.TEM

$0-100%

Opko HealthOPK

$0—

Other financials

Income statement

See full

Revenue$201.7M+11.2%

Gross profit$91.9M+18.9%

Operating income-$9.8M+79.5%

Net income$2.2M+105%

EPS (diluted)$0.02+106%

Balance sheet

See full

Cash & equivalents$145.5M-5.9%

Total debt$448.4M+534%

Total equity$785.7M-8.0%

Total assets$1.4B-3.0%

Cash flow

See full

Operating cash flow$20.0M-1.8%

CapEx$8.2M+30.0%

Free cash flow-$13.1M+56.0%

Valuation

See full

Market cap$1.74B+158%

Enterprise value$2.05B+246%

P/S2.3×+1.3×

Profitability

See full

Gross margin43.9%0.0pp

Operating margin-8.9%-2.8pp

Net margin-6.8%-2.4pp

FCF margin-4.9%—

Returns & leverage

See full

Return on equity-6.3%-2.0pp

Debt / equity0.6×+0.5×

Current ratio3.6×-0.3×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired.

The official record: NeoGenomics’s 10-Q, filed October 28, 2025, on SEC EDGAR. View the filing →

Ask your AI about NeoGenomics's acquisitions.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NeoGenomics's acquisitions?: NeoGenomics (NEO) reported acquisitions of $463K in Q3 2025.
What does acquisitions mean?: Cash paid for business acquisitions net of cash acquired in the target company — the primary M&A cash flow line.